Model Estimates Relapse Risk in Vasculitis
A post hoc analysis of the PEXIVAS trial developed a model estimating two-year relapse risk in ANCA-associated vasculitis after remission.
Updated on Nov. 2, 2026 in Stroke
A study published September 22, 2026 in Annals of the Rheumatic Diseases developed a model estimating two-year relapse risk in ANCA-associated vasculitis. The analysis drew on 649 PEXIVAS trial participants who achieved remission, and 100 (15.4%) relapsed within two years.
Why it matters
The model offers clinicians a way to estimate which patients with severe ANCA-associated vasculitis may face a higher chance of relapse after remission. It remains a research tool that requires validation before any clinical use.
The analysis is a post hoc study of 649 remitted participants from the 704-person PEXIVAS trial, with 100 (15.4%) relapsing within two years and a discrimination statistic of 0.709. The model has not yet been tested in independent cohorts using newer maintenance therapies.
The players
PEXIVAS trial
The PEXIVAS trial is a large multicenter randomized study of treatments for severe ANCA-associated vasculitis, whose participant data formed the basis of this analysis.
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases is a peer-reviewed medical journal covering rheumatology and musculoskeletal research, where the study was published.
The details
Researchers assessed candidate predictors with Cox proportional hazards and LASSO regression, and the final model included sex, ANCA subtype, nonhemorrhagic respiratory involvement, mucous membrane or eye involvement, estimated glomerular filtration rate at remission, and oral cyclophosphamide and rituximab induction. Internal validity was checked with 1,000 bootstrap samples.
Timeline
Remission occurred a median of 86 days after trial enrollment.
Relapse occurred a median of 195 days after remission.
The study was published online September 22, 2026.
Health Landscape
The study builds on the PEXIVAS trial, which compared treatment strategies in severe ANCA-associated vasculitis, by using its data to predict relapse. Its model still requires external validation before it can inform care in settings using contemporary maintenance therapies.
For patients with severe ANCA-associated vasculitis, the model could eventually help clinicians judge how closely to monitor for relapse after remission. Until it is validated, it does not change current treatment or monitoring decisions.
The takeaway
Relapse risk in ANCA-associated vasculitis may be estimable from baseline and remission-stage clinical features. Patients and clinicians should await external validation before relying on any such estimate.
Further reading
Explore more in our Stroke coverage.
Source note: This article includes information reported by Renal and Urology News.
